These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9796889)

  • 21. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
    Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
    Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR
    Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
    Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B
    An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study.
    Yoshida H; Ishikawa T; Ayaori M; Shige H; Ito T; Suzukawa M; Nakamura H
    Atherosclerosis; 1998 Jul; 139(1):179-87. PubMed ID: 9699906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
    Lahdenperä S; Tilly-Kiesi M; Vuorinen-Markkola H; Kuusi T; Taskinen MR
    Diabetes Care; 1993 Apr; 16(4):584-92. PubMed ID: 8462384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
    Vessby B; Lithell H; Boberg J; Hellsing K; Werner I
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):32-7. PubMed ID: 798194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gemfibrozil in the treatment of lipid metabolism disorders].
    Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Klin Med (Mosk); 1994; 72(1):37-41. PubMed ID: 8196321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies.
    Tsai MY; Yuan J; Hunninghake DB
    Atherosclerosis; 1992 Jul; 95(1):35-42. PubMed ID: 1642690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evaluation of lipoprotein changes during gemfibrozil treatment.
    Janus ED; Costa D; Ononogbu IC; Lewis B
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):76-7. PubMed ID: 1019156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
    Vázquez M; Zambón D; Hernández Y; Adzet T; Merlos M; Ros E; Laguna JC
    Br J Clin Pharmacol; 1998 Mar; 45(3):265-9. PubMed ID: 9517370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemfibrozil in dyslipidaemia.
    Kundu SC; Roxy S; Batabyal SK
    J Assoc Physicians India; 1990 Feb; 38(2):156-9. PubMed ID: 2199426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemfibrozil in a group of diabetics.
    de Salcedo I; Gorringe AL; Silva JL; Santos JA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):64-70. PubMed ID: 1019155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Gemfibrozil Study.
    Manninen V
    Acta Med Scand Suppl; 1985; 701():83-8. PubMed ID: 3907298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
    Lakatos J; Molnár M; Tóth K
    Acta Physiol Hung; 1996; 84(4):433-5. PubMed ID: 9328624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.
    Andersen P; Smith P; Seljeflot I; Brataker S; Arnesen H
    Thromb Haemost; 1990 Apr; 63(2):174-7. PubMed ID: 2194314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators.
    Vinik AI; Colwell JA
    Diabetes Care; 1993 Jan; 16(1):37-44. PubMed ID: 8422814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia.
    Hoogerbrugge N; Kerkhofs LG; Jansen H
    J Intern Med; 1998 May; 243(5):355-9. PubMed ID: 9651557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study.
    Leaf DA; Connor WE; Illingworth DR; Bacon SP; Sexton G
    JAMA; 1989 Dec; 262(22):3154-60. PubMed ID: 2681858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.